HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methylthioinosine

6-(Methylthio)-9-beta-D-ribofuranosylpurine. An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.
Also Known As:
6-Methylthiopurine Riboside; 6 Methylmercaptopurine Riboside; 6 Methylthiopurine Riboside; Riboside, 6-Methylmercaptopurine; Riboside, 6-Methylthiopurine; 6-Methylmercaptopurine Riboside; Inosine, 6-S-methyl-6-thio-
Networked: 23 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Han, Jiaqi: 1 article (08/2022)
2. Jin, Siyao: 1 article (08/2022)
3. Mei, Dong: 1 article (08/2022)
4. Sun, Ning: 1 article (08/2022)
5. Wang, Xiaoling: 1 article (08/2022)
6. Xu, Jiamin: 1 article (08/2022)
7. Zhao, Libo: 1 article (08/2022)
8. Bonnac, Laurent F: 1 article (12/2021)
9. Cheeran, Maxim C-J: 1 article (12/2021)
10. Dreis, Christine D: 1 article (12/2021)

Related Diseases

1. Neoplasms (Cancer)
02/01/1968 - "Studies of combination 6-mercaptopurine (NSC-755) and 6-methylmercaptopurine riboside (NSC-40774) in patients with acute leukemia and metastatic cancer."
09/04/1991 - "Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens."
08/01/1992 - "High performance liquid chromatography and nuclear magnetic resonance spectroscopy measurements of biochemical changes resulting from treatment with N-(phosphonacetyl)-L-aspartate plus 6-methylmercaptopurine riboside plus 6-aminonicotinamide indicated a severe depletion of cellular energy levels in the treated tumors. "
12/01/1997 - "To evaluate the effects of biochemical modulation by N-(phosphonacetyl)-L-aspartate (PALA), 6-methylmercaptopurine riboside (MMPR), and 6-aminonicotinamide (6AN), (PALA + MMPR + 6AN is referred to as PMA) on tumor radiosensitivity, and evaluate the efficacy of the addition of 5-FU to the PMA + XRT regimen for enhancement of tumor response to radiation without exceeding normal tissue tolerance. "
02/01/2001 - "It is necessary to deplete tumor ATP levels seveerely (>85%) by a combination of agents that block both synthesis (6-methylmercaptopurine riboside, a purine de novo synthesis inhibitor) and generation of ATP(6-aminonicotinamide, an inhibitor of glycolysis.) Cell viability cannot be sustained if the intracellular ATP level is reduced to 15% of normal or below. "
2. Leukemia
3. Pancreatic Neoplasms (Pancreatic Cancer)
4. Neuroblastoma
5. Hepatocellular Carcinoma (Hepatoma)

Related Drugs and Biologics

1. sparfosic acid (PALA)
2. Fluorouracil (Carac)
3. 6-Aminonicotinamide (6 Aminonicotinamide)
4. Mercaptopurine (6 Mercaptopurine)
5. Vincristine (Oncovin)
6. Purine Nucleosides
7. Methionine (L-Methionine)
8. Cytarabine (Cytosar-U)
9. Cyclophosphamide (Cytoxan)
10. 5'-methylthioinosine